The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase Ib study of dulanermin combined with first-line FOLFOX plus bevacizumab (BV) in patients (Pts) with metastatic colorectal cancer (mCRC).
Mark Kozloff
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Wells A. Messersmith
Consultant or Advisory Role - Genentech (U)
Research Funding - Genentech
Amy V. Kapp
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
Avi Ashkenazi
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
Stephanie Royer-Joo
Consultant or Advisory Role - Genentech
Chia C. Portera
Employment or Leadership Position - Genentech
Stock Ownership - Roche/Genentech
Zev A. Wainberg
Consultant or Advisory Role - Genentech
Honoraria - Genentech